Many of the most potent human oncoproteins belong to a class of proteins called transcription factors, but designing small molecule drugs that target transcription factors is a major challenge, especially when treating aggressive forms of prostate cancer. An international team of researchers from the Institute for Research in Biomedicine in Barcelona, the Max Planck Institute...